Toll Like Receptor 4 (hToll or CD284 or TLR4)-Pipeline Review, H2 2017

Toll Like Receptor 4 (hToll or CD284 or TLR4)-Pipeline Review, H2 2017


  • Products Id :- GMDHC0944TDB
  • |
  • Pages: 119
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Toll Like Receptor 4 (hToll or CD284 or TLR4)-Pipeline Review, H2 2017

Summary

Toll Like Receptor 4 (hToll or CD284 or TLR4)-Toll-like receptor 4 is a protein encoded by the TLR4 gene. This receptor is mostly expressed in placenta, and in myelomonocytic subpopulation of the leukocytes. It is involved in LPS-independent inflammatory responses triggered by free fatty acids, such as palmitate, and Ni2+. It responses are triggered by Ni2+ require non-conserved. In complex with TLR6 promotes sterile inflammation in monocytes in response to oxidized low-density lipoprotein (oxLDL).

Toll Like Receptor 4 (hToll or CD284 or TLR4) pipeline Target constitutes close to 39 molecules. Out of which approximately 33 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 10, 3, 16 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 6 molecules, respectively. Report covers products from therapy areas Oncology, Infectious Disease, Gastrointestinal, Immunology, Respiratory, Cardiovascular, Central Nervous System, Genito Urinary System And Sex Hormones, Dermatology, Ear Nose Throat Disorders, Mouth and Dental Disorders, Musculoskeletal Disorders, Ophthalmology and Other Diseases which include indications Pulmonary Inflammation, Breast Cancer, Inflammation, Inflammatory Bowel Disease, Liver Fibrosis, Non-Alcoholic Steatohepatitis (NASH), Atherosclerosis, Autoimmune Hepatitis, Drug Addiction, Kidney Disease, Kidney Fibrosis, Rheumatoid Arthritis, Sepsis, Soft Tissue Sarcoma, Traumatic Brain Injury, Acne Vulgaris, Acute Ischemic Stroke, Acute Lung Injury, Alcohol Addiction, Amyotrophic Lateral Sclerosis, Asthma, Atopic Dermatitis, Autoimmune Disorders, Bacterial Sepsis, Burns, Cervical Cancer, Crohn Disease (Regional Enteritis), Ebolavirus Infections (Ebola Hemorrhagic Fever), Endotoxemia, Epilepsy, Escherichia coli Infections, Follicular Lymphoma, Globoid Cell Leukodystrophy (Krabbe Disease), Hearing Disorders, Hepatitis B, Hepatitis C, Hepatocellular Carcinoma, Human Immunodeficiency Virus (HIV) Infections (AIDS), Human Papillomavirus (HPV) Associated Cancer, Human Papillomavirus Infections, Ischemia Reperfusion Injury, Keratoconjunctivitis sicca (Dry Eye), Leishmaniasis (Kala-Azar), Listeriosis, Lung Cancer, Marburgvirus Infections (Marburg Hemorrhagic Fever), Melanoma, Merkel Cell Carcinoma, Metastatic Melanoma, Multiple Sclerosis, Necrotizing Enterocolitis, Neuropathic Pain, Non Alcoholic Fatty Liver Disease (NAFLD), Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Non-Hodgkin Lymphoma, Opium Withdrawal Syndrome, Osteoarthritis, Ovarian Cancer, Pancreatic Cancer, Peanut Allergy, Phlebovirus Infections, Post-Traumatic Stress Disorder (PTSD), Primary Progressive Multiple Sclerosis (PPMS), Prostate Cancer, Pseudomonas aeruginosa Infections, Recurrent Glioblastoma Multiforme (GBM), Rosacea, Secondary Progressive Multiple Sclerosis (SPMS), Septic Shock, Trauma, Wounds, Xerostomia and Zika Virus Infections.

The latest report Toll Like Receptor 4-Pipeline Review, H2 2017, outlays comprehensive information on the Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 4 (hToll or CD284 or TLR4)

The report reviews Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics and enlists all their major and minor projects

The report assesses Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Toll Like Receptor 4 (hToll or CD284 or TLR4)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Toll Like Receptor 4 (hToll or CD284 or TLR4) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Toll Like Receptor 4 (hToll or CD284 or TLR4)-Overview 7

Toll Like Receptor 4 (hToll or CD284 or TLR4)-Therapeutics Development 8

Products under Development by Stage of Development 8

Products under Development by Therapy Area 9

Products under Development by Indication 10

Products under Development by Companies 15

Products under Development by Universities/Institutes 22

Toll Like Receptor 4 (hToll or CD284 or TLR4)-Therapeutics Assessment 25

Assessment by Mechanism of Action 25

Assessment by Route of Administration 27

Assessment by Molecule Type 29

Toll Like Receptor 4 (hToll or CD284 or TLR4)-Companies Involved in Therapeutics Development 31

AptaTargets SL 31

Batu Biologics Inc 31

Biomedica Management Corp 32

Eisai Co Ltd 32

eTheRNA Immunotherapies NV 33

EyeGene Inc 33

Formune SL 34

GlaxoSmithKline Plc 34

Harbor Therapeutics Inc 35

Immune Design Corp 35

Immunovo BV 36

Kyorin Pharmaceutical Co Ltd 36

NovImmune SA 37

Sanofi 37

TaiwanJ Pharmaceuticals Co Ltd 38

Vascular Biogenics Ltd 39

Toll Like Receptor 4 (hToll or CD284 or TLR4)-Drug Profiles 40

ApTOLL-Drug Profile 40

AyuV-25-Drug Profile 41

Biologic to Agonize TLR4 for Drug Addiction-Drug Profile 42

C-34-Drug Profile 43

CIA-05-Drug Profile 44

CMB-305+G-100-Drug Profile 45

CRX-526-Drug Profile 46

DMT-210-Drug Profile 47

Drugs to Agonize TLR4 for Oncology-Drug Profile 49

ECF-843-Drug Profile 50

ECI-006-Drug Profile 52

EDA-HPVE7-Drug Profile 53

eritoran tetrasodium-Drug Profile 54

G-100-Drug Profile 56

Glyco-23-Drug Profile 60

GSK-1795091-Drug Profile 61

HE-3286-Drug Profile 62

hp-91-Drug Profile 64

ibudilast-Drug Profile 65

ISAS-01-Drug Profile 75

JKB-117-Drug Profile 76

JKB-119-Drug Profile 77

JKB-121-Drug Profile 78

naltrexone hydrochloride-Drug Profile 79

NI-0101-Drug Profile 81

P-13-Drug Profile 83

P-16-Drug Profile 84

P-7-Drug Profile 85

P-MAPA-Drug Profile 86

PEPA-10-Drug Profile 88

rabeximodum-Drug Profile 89

SAR-439794-Drug Profile 90

Small Molecules to Antagonize TLR-4 for CNS Disorders-Drug Profile 91

Small Molecules to Antagonize TLR2 and TLR4 for Immunology and Inflammation-Drug Profile 92

Small Molecules to Antagonize TLR4 for Acute Lung Injury and Bacterial Sepsis-Drug Profile 93

Synthetic Peptide to Antagonize TLR-4 for Oncology, Immunology and Infectious Disease-Drug Profile 94

TWJ-201-Drug Profile 95

VB-201-Drug Profile 96

VB-703-Drug Profile 99

Toll Like Receptor 4 (hToll or CD284 or TLR4)-Dormant Products 100

Toll Like Receptor 4 (hToll or CD284 or TLR4)-Discontinued Products 103

Toll Like Receptor 4 (hToll or CD284 or TLR4)-Product Development Milestones 104

Featured News & Press Releases 104

Appendix 115

Methodology 115

Coverage 115

Secondary Research 115

Primary Research 115

Expert Panel Validation 115

Contact Us 115

Disclaimer 116

List of Figures

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Top 10 Indications, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

List of Tables

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indications, H2 2017

Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Indications, H2 2017 (Contd..3), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1)

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Products under Development by Companies, H2 2017 (Contd..4), H2 2017

Number of Products under Investigation by Universities/Institutes, H2 2017

Products under Investigation by Universities/Institutes, H2 2017

Products under Investigation by Universities/Institutes, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pipeline by AptaTargets SL, H2 2017

Pipeline by Batu Biologics Inc, H2 2017

Pipeline by Biomedica Management Corp, H2 2017

Pipeline by Eisai Co Ltd, H2 2017

Pipeline by eTheRNA Immunotherapies NV, H2 2017

Pipeline by EyeGene Inc, H2 2017

Pipeline by Formune SL, H2 2017

Pipeline by GlaxoSmithKline Plc, H2 2017

Pipeline by Harbor Therapeutics Inc, H2 2017

Pipeline by Immune Design Corp, H2 2017

Pipeline by Immunovo BV, H2 2017

Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2017

Pipeline by NovImmune SA, H2 2017

Pipeline by Sanofi, H2 2017

Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H2 2017

Pipeline by Vascular Biogenics Ltd, H2 2017

Dormant Products, H2 2017

Dormant Products, H2 2017 (Contd..1), H2 2017

Dormant Products, H2 2017 (Contd..2), H2 2017

Discontinued Products, H2 2017

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

AptaTargets SL

Batu Biologics Inc

Biomedica Management Corp

Eisai Co Ltd

eTheRNA Immunotherapies NV

EyeGene Inc

Formune SL

GlaxoSmithKline Plc

Harbor Therapeutics Inc

Immune Design Corp

Immunovo BV

Kyorin Pharmaceutical Co Ltd

NovImmune SA

Sanofi

TaiwanJ Pharmaceuticals Co Ltd

Vascular Biogenics Ltd

Toll Like Receptor 4 (hToll or CD284 or TLR4) Therapeutic Products under Development, Key Players in Toll Like Receptor 4 (hToll or CD284 or TLR4) Therapeutics, Toll Like Receptor 4 (hToll or CD284 or TLR4) Pipeline Overview, Toll Like Receptor 4 (hToll or CD284 or TLR4) Pipeline, Toll Like Receptor 4 (hToll or CD284 or TLR4) Pipeline Assessment

select a license
Single User License
USD 3500 INR 245000
Site License
USD 7000 INR 490000
Corporate User License
USD 10500 INR 735000

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com